Recent investigations have converged on the intersection of GLP|GIP|GCGR agonist therapies and dopaminergic signaling. While GCGR stimulators are commonly employed for managing type 2 diabetes mellitus, their potential effects on motivation circuits, specifically mediated by DA pathways, are gaining significant focus. This paper details a brief … Read More